Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 271

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 271
---
 factors, including, among others, the risks described in the “Risk Factors” section and elsewhere in this Annual Report.

As used in this discussion
and analysis, unless the context indicates otherwise, the terms the “Company,” “Harrow” “we,” “us”
and “our” refer to Harrow, Inc. and its consolidated subsidiaries, including Imprimis RxNJ, LLC, Imprimis NJOF, LLC, ImprimisRx,
LLC, Harrow IP, LLC and Harrow Eye, LLC.

Overview 

We are a leading eyecare pharmaceutical
company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market.
We help U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription
pharmaceutical products accessible and affordable to millions of Americans each year. We own commercial rights to one of the largest
portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. We also own
and operate ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical-compounding businesses.

Factors Affecting Our Performance

We
believe the primary factors affecting our performance are our ability to increase revenues of our branded pharmaceutical products,
proprietary compounded formulations and certain non-proprietary products, grow and gain operating efficiencies in our operations,
avoid or mitigate any potential regulatory-related restrictions, optimize pricing and obtain reimbursement options for our drug
products, and continue to pursue development and commercialization opportunities for certain of our ophthalmology and other assets
that we have not yet made commercially available. We believe we have built a tangible and intangible infrastructure that will allow
us to scale revenues efficiently in the near and long-term. All of these activities will require significant costs and other
resources, which we may not have or be able to obtain from operations or other sources. See “Liquidity and Capital
Resources” below.

Recent Developments 

The following describes certain
developments in 2024 and 2025 to date that are important to understand our financial condition, results of operations, and expectations. See the notes
to our consolidated financial statements included in this Annual Report for additional information about certain developments.

VEVYE
Access for All

In
March 2025, we announced a patient access program called VEVYE Access for All.  The program is designed to increase patient access
to VEV